

Cognition and Behavior

The Role of Glutamatergic and Dopaminergic Neurons in the Periaqueductal Gray/Dorsal Raphe: Separating Analgesia and Anxiety

 Norman E. Taylor,¹ JunZhu Pei,²  Jie Zhang,¹ Ksenia Y. Vlasov,²  Trevor Davis,³ Emma Taylor,⁴ Feng-Ju Weng,² Christa J. Van Dort,⁵ Ken Solt,⁵ and  Emery N. Brown^{5,6}

<https://doi.org/10.1523/ENEURO.0018-18.2019>

¹University of Utah, Salt Lake City 84112, UT, ²Massachusetts Institute of Technology, Cambridge 02139, MA, ³Brigham Young University, Provo 84602, UT, ⁴University of Massachusetts, Lowell 01854, MA, ⁵Massachusetts General Hospital, Boston 02114, MA, and ⁶Picower Institute for Learning and Memory, MIT, Cambridge, MA 02139

Abstract

The periaqueductal gray (PAG) is a significant modulator of both analgesic and fear behaviors in both humans and rodents, but the underlying circuitry responsible for these two phenotypes is incompletely understood. Importantly, it is not known if there is a way to produce analgesia without anxiety by targeting the PAG, as modulation of glutamate or GABA neurons in this area initiates both antinociceptive and anxiogenic behavior. While dopamine (DA) neurons in the ventrolateral PAG (vlPAG)/dorsal raphe display a supraspinal antinociceptive effect, their influence on anxiety and fear are unknown. Using DAT-cre and Vglut2-cre male mice, we introduced designer receptors exclusively activated by designer drugs (DREADD) to DA and glutamate neurons within the vlPAG using viral-mediated delivery and found that levels of analgesia were significant and quantitatively similar when DA and glutamate neurons were selectively stimulated. Activation of glutamatergic neurons, however, reliably produced higher indices of anxiety, with increased freezing time and more time spent in the safety of a dark enclosure. In contrast, animals in which PAG/dorsal raphe DA neurons were stimulated failed to show fear behaviors. DA-mediated antinociception was inhibitable by haloperidol and was sufficient to prevent persistent inflammatory pain induced by carrageenan. In summary, only activation of DA neurons in the PAG/dorsal raphe produced profound analgesia without signs of anxiety, indicating that PAG/dorsal raphe DA neurons are an important target involved in analgesia that may lead to new treatments for pain.

Key words: analgesia; anxiety; dopamine; DREADDs; periaqueductal gray

Significance Statement

Clinicians have long had the goal of separating analgesia from anxiety when using deep brain electrical stimulation of the periaqueductal gray (PAG) for difficult to treat pain. Here, we show that selective activation of dopamine (DA) neurons within the PAG produces analgesia without other behavioral effects, while stimulating glutamate neurons mediates stress-induced anxiety and analgesia. Our results suggest that DA agonists may represent a novel class of analgesic drugs and elucidate target neurons that could mediate their effect.

Introduction

The midbrain periaqueductal gray (PAG) plays a significant role in pain and analgesia, fear and anxiety, and

cardiovascular control (Behbehani, 1995; Millan, 2002; Tovote et al., 2016). Electrical stimulation of the PAG and periventricular gray in both animals (Reynolds, 1969) and

Received January 10, 2018; accepted January 29, 2019; First published February 06, 2019.

The authors declare no competing financial interests.

Author contributions: N.E.T., C.J.V.D., K.S., and E.N.B. designed research; N.E.T., J.P., J.Z., F.-J.W., K.Y.V., E.T., and T.D. performed research; N.E.T., J.P., J.Z., and E.N.B. analyzed data; N.E.T. and E.N.B. wrote the paper.

humans (Hosobuchi et al., 1977; Richardson and Akil, 1977) produces profound antinociception, and has been used clinically to alleviate difficult to treat pain. While some patients receive considerable analgesic benefit (Bittar et al., 2005), the use of electrical stimulation of the PAG as a clinical analgesic modality has been limited because of fear and anxiety side effects in some patients (Shapira et al., 2006). A long-standing question in clinical pain research is whether there is a way to separate the generation of analgesia from anxiety when targeting the PAG (Fardin et al., 1984).

Early studies examined the effects of location within the PAG on antinociceptive and anxiety behaviors. Both electrical and pharmacologic stimulation of dorsal and lateral areas of the PAG produce flight reactions such as running and jumping, while there appear to be purely analgesic zones within the ventrolateral PAG (vIPAG) and dorsal raphe (Fardin et al., 1984). However, this is not a consistent finding, as freezing behavior can be elicited by pharmacologic stimulation of the vIPAG (Morgan et al., 1998; Kim et al., 2013), suggesting that a specific neuron type within the vIPAG might be responsible for the purely analgesic effect.

The vIPAG is comprised of a diverse population of neurons including glutamatergic, GABAergic, serotonergic and dopaminergic cells. GABAergic neurons in the vIPAG have particularly dense mu opioid receptor expression, and opioids are able to inhibit vIPAG GABAergic interneurons (Vaughan and Christie, 1997; Vaughan et al., 1997) leading to activation of glutamatergic projections to the rostral ventral medulla (RVM; Wiklund et al., 1988; Beitz, 1990; Reichling and Basbaum, 1990). In addition, a subset of GABAergic neurons also project directly to the RVM (Morgan et al., 2008). This classic descending pain inhibition circuit terminates at the dorsal horn of the spinal cord and powerfully modulates ascending nociceptive signals. However, in addition to their antinociceptive effects, opioids and GABA antagonists microinjected into the vIPAG also produce fear behaviors (Jacquet and Lajtha, 1974; Tomaz et al., 1988) and selective inhibition of local GABAergic vIPAG neurons induce freezing (Tovote et al., 2016). Therefore, vIPAG GABAergic neurons cannot be targeted to produce exclusive analgesia effects.

Glutamatergic neurons in the vIPAG are also involved in antinociception. Both optogenetic (Tovote et al., 2016) and chemogenetic (Samineni et al., 2017) activation of vIPAG glutamatergic neurons produce analgesia, and project to the RVM in the descending pain inhibition circuit. However, they also serve as the output neurons from

the vIPAG in the circuit mediating fear and anxiety responses to a threat. GABAergic inputs to the vIPAG from the central nucleus of the amygdala (CEA) and the posterior hypothalamus (Falconi-Sobrinho et al., 2017) mediate glutamatergic outputs to pre-motor targets in the magnocellular nucleus of the medulla which mediate freezing (Miguel and Nunes-de-Souza, 2006; Tovote et al., 2016). Therefore, vIPAG glutamatergic neurons also cannot be targeted to produce exclusive analgesia effects.

One potential target could be vIPAG/dorsal raphe dopamine (DA) neurons. There is an understudied population of DA neurons in the vIPAG/dorsal raphe which is thought to exert analgesic effects (Suckow et al., 2013). Chemical lesion of PAG DA neurons attenuates opioid-induced antinociception (Flores et al., 2004) while local injection of the DA agonist apomorphine into the vIPAG produces antinociception (Meyer et al., 2009; Schoo et al., 2017). Furthermore, optogenetic activation of vIPAG/dorsal raphe DA neurons results in DA release in the bed nucleus of the stria terminalis (BNST) and a supraspinal antinociceptive effect (Li et al., 2016). The effects of vIPAG/dorsal raphe DA neurons on fear and anxiety behaviors, however, are completely unknown. In this study, we use a chemogenetic approach to specifically target dopaminergic and glutamatergic neurons in the vIPAG to test the hypothesis that dopaminergic neurons are antinociceptive without being anxiogenic.

Materials and Methods

Experimental animals

Adult male DAT-Cre (The Jackson Laboratory, stock number 006660) and vGlut2-ires-Cre mice (The Jackson Laboratory, stock number 016963), weighing 20–25 g, were used for all experiments. Mice were kept on a 12/12 h light/dark cycle (lights on at 7 A.M., lights off at 7 P.M.) with *ad libitum* access to food and water. Mice had a minimum of three weeks to recover after surgery, and at least 3 d of rest were provided after each experiment. All animal procedures were reviewed and approved by the authors Animal Care and Use Committee.

Drugs

The following drugs were used in this study: the designer receptors exclusively activated by designer drugs (DREADD) activator clozapine-N-oxide (CNO; C0832, Sigma-Aldrich), SCH-23390 (D1 receptor antagonist, D054, Sigma-Aldrich), raclopride (D2 receptor antagonist, R121, Sigma-Aldrich), haloperidol (non-specific DA receptor antagonist, 67457-426-12, Mylan), and the inflammatory agent carrageenan (C1013, Sigma-Aldrich). All drugs were diluted in saline.

Chemogenetic manipulation

To induce the expression of DREADDs in the vIPAG, 300nl of adeno-associated virus (AAV) carrying either the AAV8-hSyn-DIO-hM3D(Gq)-mCherry (excitatory, hM3), AAV8-hSyn-DIO-hM4D(Gi)-mCherry (inhibitory, hM4) vectors, or a virus containing only a fluorescent tag without a receptor (AAV8-hSyn-DIO-mCherry, UNC Vector Core),

This work was supported by National Institutes of Health Grants TR01-GM104948 and 1K08GM121951-01 and the Foundation for Anesthesia Education and Research Grant MRTG-BS-02/15/2014Ta.

Correspondence should be addressed to Norman E. Taylor at norman.taylor@hsc.utah.edu.

<https://doi.org/10.1523/ENEURO.0018-18.2019>

Copyright © 2019 Taylor et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

were injected bilaterally at -4.7 mm anterior/posterior, ± 0.5 mm lateral, and -2.75 mm dorsal/ventral to bregma. Briefly, mice were anesthetized with 2% isoflurane and placed in a stereotaxic frame (David Kopf Instruments). An incision was made in the skin, and craniotomies were made above the target region. The injections were performed using a motorized stereotaxic injector (Stoelting) and the mice recovered for three weeks to allow optimal viral expression.

Experimental procedures

Nociceptive behavior testing

To evaluate nociception, thermal withdrawal latencies and mechanical withdrawal thresholds were assayed as previously described (Samineni et al., 2017). The Hargreaves test was performed to evaluate heat sensitivity thresholds, measuring latency of withdrawal to a radiant heat source (IITC Life Science, Model 390). The radiant heat was applied to the plantar surface of both hind paw and the latency to evoke a withdrawal was measured. Three to five replicates, measured every 5 min over 20 min, were acquired per hind paw per mouse, and the values for both paws were averaged. At least 2 d later, von Frey filaments (Stoelting Co.) were used to evaluate the mechanical nociceptive threshold. Filaments were applied, also to the plantar surface of both hind paws of the mice, five times, increasing thickness until a withdrawal response was observed three times. The force of the corresponding filament was recorded as the mechanical nociceptive threshold for each mouse.

For the nociceptive behavior evaluations, mice were habituated to the assessment chambers starting two weeks after viral injections. The baseline nociceptive thresholds were determined on the 3rd week postsurgery. Following the baseline measurements, mice received intraperitoneal injection of saline, CNO alone (1 mg/kg), CNO plus SCH-23390 (0.5 mg/kg), CNO plus raclopride (0.5 mg/kg), or CNO plus haloperidol (0.3 mg/kg), in a blinded fashion. Then, the mice were placed back within their individual Plexiglas compartments for 60 min before beginning behavioral assessment. Paw withdrawal latencies or thresholds were collected between the first and second hour after injection. The minimal dose of CNO needed to activate the DREADDs, and the minimal dose of antagonists required to achieve peak effect, were determined by previous experiments (data not shown).

Fear behavior testing

After thermal nociception testing, mice were individually placed into the center of an open field test environment of dark acrylic plastic ($40 \times 40 \times 40$ cm), under dim lit conditions with the same experimenter in the room. Their movements were recorded for 5 min using a USB camera and video tracking system (Any-Maze, Stoelting Co.). At least 2 d later, following mechanical nociception testing, mice were individually placed into the dark side of a light-and-dark test environment of acrylic plastic ($40 \times 40 \times 40$ cm), and their movements within the light areas of the box were recorded for 5 min using the video tracking system.

Inflammatory pain model

To evaluate the role of dopaminergic vPAG/dorsal raphe neurons in pain produced by inflammation, 25 μ l of a

20 mg/ml solution of carrageenan, dissolved in saline, was injected subcutaneously into the plantar surface of the hind paw of DAT-cre and vGlut2-cre mice, as previously described (Hargreaves et al., 1988). Three hours later, mice received intraperitoneal injection of CNO, and 1 h later, paw withdrawal latency to a thermal stimulus (Hargreaves test) was evaluated.

In vitro electrophysiology

Patch clamp slice preparation

Identified mice were anesthetized with isoflurane and swiftly decapitated. The brains were harvested and rapidly immersed in ice cold carbonated (95% O₂ and 5% CO₂)-cutting solution composed of 105 mM *N*-methyl-D-glucamine, 26 mM NaHCO₃, 15 mM glucose, 10 mM MgCl₂, 2.5 mM KCl, 1.24 mM NaH₂PO₄, 0.5 mM CaCl₂, and 1 mM Na ascorbate at an osmolality of 300 mOsm. The pH of this solution was titrated to 7.3 with HCl. The brain tissue was subsequently blocked and sliced into 350- μ m coronal sections with a vibrating blade microtome (VT1200, Leica). Slices that contained the vPAG were relocated into an incubation chamber filled with warm (32°C) carbonated cutting solution for 10 min followed by recovery solution (32°C) containing 50% cutting solution and 50% artificial CSF (ACSF) for 20 min. The coronal brain slices were then held in a holding chamber containing carbonated ACSF (pH 7.3) composed of 119 mM NaCl, 26 mM NaHCO₃, 2.5 mM KCl, 2.5 mM CaCl₂, 1.3 MgCl₂, and 10 mM glucose at an osmolality of 300 mOsm at room temperature ($\sim 23^\circ\text{C}$) for at least 1 h before resuming patch experiments.

Electrophysiology recordings

Following at least 1 h of recovery, the coronal brain slices were transferred to a recording chamber circulated with carbonated ACSF in room temperature ($\sim 23^\circ\text{C}$) at a flow rate of 2 ml/min. A borosilicate glass pipette (tip resistance between 3 and 6 M Ω) was filled with a solution composed of 130 mM K-gluconate, 10 mM KCl, 10 mM HEPES, 4 mM Mg-ATP, 0.2 mM EGTA, and 0.5 mM Na-GTP at an osmolality of 290 mOsm (pH 7.25). CNO-evoked currents were recorded in voltage-clamp mode with membrane potential held at -70 mV, and CNO-evoked spikes were recorded in current-clamp mode with a holding potential at around -55 mV. DREADD-mCherry-expressing cells were identified by mCherry expression, and cells were stimulated using 10 μ M CNO. Data, acquired with an Axon Multiclamp 700B amplifier and a Digidata 1440 digitizer (Molecular Devices), were analyzed using Axon Clampfit. Recordings with access resistance >25 M Ω or with changes in access resistance $>15\%$ were discarded.

Immunohistochemistry

After all experiments were completed, viral expression and localization was verified via histologic analysis. Dat-cre animals were perfused with phosphate buffered saline followed by neutral buffered formalin. The brains were postfixed in formalin overnight, and sliced at 60 μ m using a Leica VT1200 S vibratome (Leica Microsystems Inc.). Specific expression of DREADDs in DA neurons was con-

firmed by colocalization of mCherry (from AAV expression) with immunohistochemical staining for tyrosine hydroxylase (TH), a marker of DA neurons (mouse anti-TH, 1:1000 dilution, Millipore catalog #MAB318), using the secondary antibody of goat anti-mouse conjugated to Alexa Fluor 488 (1:200 dilution, catalog #A-11001, Invitrogen). Cells were counterstained with 4',6-diamidino-2-phenylindole (DAPI; catalog #H-1200, Vectashield) for nuclear visualization. Images were taken with a Zeiss Axio M2 microscope (Zeiss). Confirmation of viral expression in the correct brain region was performed by comparing images to a Mouse Brain Atlas (Paxinos et al., 2001).

Fluorescent *in situ* hybridization (FISH)

Brains were swiftly harvested and immediately flash frozen in a beaker filled with a bilayer of 1-methylbutane and 1-bromobutane on dried iced and subsequently stored in -80°C . The brains were sectioned on a cryostat and mounted on Superfrost Plus Gold slides (25×75 mm, Erie Scientific). One hour before sectioning, brains and slides were equilibrated to -20°C in the cryostat. The specified brains were serially sectioned coronally at $12 \mu\text{m}$ and mounted onto slides via the warmth of the hand. The mounted specimens were dried for 1 h inside the cryostat then stored at -80°C . Double-label FISH was performed using RNAScope Manual Fluorescent Multiplex kit User Manual specified for Fresh Frozen Tissue (Advanced Cell Diagnostics). Slides were fixed in 4% paraformaldehyde (PFA) at 4°C , serially dehydrated, washed twice in phosphate buffered saline pH 7.38, and pretreated with protease IV solution for 30 min. Specimens were then incubated with target probes for mouse *vglut2* (*slc17a6* target region 1986–2998, catalog #319171, Advanced Cell Diagnostics) and *mcherry* (*mcherry* target region 23–681, catalog #431201-C2, Advanced Cell Diagnostics). Next, the slides underwent four serial amplification incubations the last of which contained fluorescent probes (Alexa Fluor 488 and Atto 550, catalog #320850, Advanced Cell Diagnostics Part of Fluorescent Multiplex kit) individually targeted to the *slc17a6* and *mcherry* probes. Finally, the slides were mounted with ProLong Diamond Antifade Mountant with DAPI (catalog #P36962, Invitrogen). Images were taken with a Zeiss Imager M2 microscope (Zeiss).

Statistical analysis

GraphPad Prism 7.02 was used to perform statistical analysis. The Shapiro–Wilk test was first performed on each set of data to test for normality. To guard against type 1 error, a one-way ANOVA was applied to data determined to be normally distributed while a Kruskal–Wallis test was applied to the remaining groups of non-parametric data. As comparisons were made between pre-treated and post-treated conditions in the same mouse in the Hargreaves and von Frey data presented in Figures 1, 2, pair-wise comparisons were made using either a paired *t* test for the normally distributed DAT-cre mice Hargreaves data, or the Wilcoxon signed rank test for the remaining paired nonparametric data. Comparisons of the open field and light/dark test endpoints were made in different groups of animals; therefore, a one-way

ANOVA was performed on each group of animals of the same strain whose data were parametric followed by a Dunnett's multiple comparison test, while a Kruskal–Wallis test was followed by a Dunn's multiple comparisons test in non-parametric data; $p < 0.05$ was considered significant in all cases. In addition, differences between experimental and control conditions were calculated, and bootstrapped 95% confidence intervals (CIs) were generated using MATLAB as confirmation of statistical significance. If the CI's did not include 0, the difference between the experimental and control conditions was deemed to be statistically significant. Data are reported in the text as the median difference between experimental and control conditions with 95% CI. Figures include the raw data as points, with bar graphs depicting the median value with 95% CIs.

Results

To determine the neurons within the PAG that could selectively produce antinociceptive behavioral phenotypes, we used a chemogenetic approach to specifically manipulate the activity of glutamatergic and dopaminergic neurons in the vIPAG and dorsal raphe. Glutamatergic neurons were targeted by local injection of AAV into the vIPAG of transgenic mice that expressed Cre under control of the vesicular glutamate transporter 2 gene (*vGlut2-cre*; Fig. 1A). Anesthetized *vGlut2-cre* mice received targeted injections of AAV carrying an excitatory DREADD (AAV8-hM3Dq, $n = 8$ mice/group), an inhibitory DREADDs construct (AAV8-hM4Di, $n = 8$ mice/group) or a virus only containing the mCherry fluorescent tag ($n = 8$). FISH demonstrated robust DREADD expression restricted to glutamate neurons in the the vIPAG and dorsal raphe (Fig. 1B,D). We observed $83 \pm 2\%$ of green-labeled *vGlut2*⁺ transcripts in the vIPAG and dorsal raphe colocalized with mcherry-labeled neurons expressing *vGlut2* RNA, and $95 \pm 2\%$ of mcherry-labeled *vGlut2* cre-expressing neurons colocalized with green-labeled *vGlut2*⁺ transcripts as shown in Figure 1C. Based on this histologic examination, no animals were excluded in the behavioral analysis. The transfection specificity and sensitivity were similar to values previously reported.

As shown in Fig. 1E, there was no significant difference between paw withdrawal latency to a thermal stimulus measured before and after intraperitoneal administration of the normally inert ligand CNO (-0.09 s, 95% CI [-1.56 , 1.50 s], Wilcoxon signed rank, $df7$, $p = 0.6875$). Likewise, there was no change in paw withdrawal threshold to a mechanical nociceptive stimulus between control animals before and after intraperitoneal CNO (0 g, 95% CI [-0.14 , 0.0 g], Wilcoxon signed rank, $df7$, $p = 0.592$), as shown in Figure 1F. CNO activation of vIPAG glutamate neurons increased both paw withdrawal latency (12.06 s, 95% CI [7.56, 12.66 s], Wilcoxon signed rank, $df7$, $p = 0.0078$) and mechanical nociceptive threshold (5 g, 95% CI [2.66, 5.23 g], Wilcoxon signed rank, $df7$, $p = 0.0002$) in *vGlut2-cre* mice, while inhibition decreased paw withdrawal latencies (-6.85 s, 95% CI [-7.83 , -3.12 s], Wilcoxon signed rank, $df6$, $p = 0.0078$) and thresholds (-0.18 g,




Figure 1. Glutamatergic neurons in the vIPAG produce antinociception **A**, Glutamatergic neurons were targeted by local vIPAG injection of AAV in transgenic mice that expressed Cre under control of the vesicular glutamate transporter 2 gene (vGluT2-cre). **B**, DREADDs expression in the vIPAG/dorsal raphe of vglut2-cre mice (RNA-FISH). **C**, $83 \pm 2\%$ of green-labeled vGluT2⁺ transcripts in the vIPAG and dorsal raphe colocalized with mCherry-labeled neurons expressing vGluT2 RNA, and $95 \pm 2\%$ of mCherry-labeled vGluT2 cre-expressing neurons colocalized with green-labeled vGluT2⁺ transcripts. **D**, DREADDs are expressed in vIPAG/dorsal raphe vGluT2⁺ neurons as demonstrated by colocalized expression in the merged image. **E, F**, Bar graphs represent the median value of the data, while the error bars are the 95% CI. White bars indicate nociceptive testing before intraperitoneal CNO injections, while green bars indicate nociceptive testing 1 h after CNO administration. Pair-wise comparisons with a Wilcoxon signed-rank test indicated no significant behavioral difference in mCherry animals ($n = 7$) after CNO treatment. CNO activation of vIPAG glutamate neurons (hM3, $n = 8$) produced analgesia as indicated by increased paw withdrawal latencies to thermal ($p = 0.0078$) and mechanical

continued

stimuli ($p = 0.0002$) in vGlut2-cre mice, while inhibition (hM4, $n = 8$) caused increased sensitivity to both thermal ($p = 0.0078$) and mechanical stimuli ($p = 0.0008$). * $p < 0.05$.

95% CI $[-0.35, -0.14$ g], Wilcoxon signed rank, df_6 , $p = 0.0008$).

Recently, it was discovered that CNO does not enter the brain after systemic injection but, rather, is rapidly converted to clozapine which binds to DREADDs with high affinity and potency and is responsible for the *in vivo* effect (Gomez et al., 2017). It is therefore significant that administration of CNO to mice expressing the mcherry tag but lacking DREADDs produced no significant difference in paw withdrawal latencies or paw withdrawal thresholds, demonstrating the absence of a non-specific CNO/clozapine effect.

Mice expressing Cre recombinase under the transcriptional control of the DA transporter promoter (DAT-cre mice) were similarly prepared, with virus containing either excitatory (hM3), inhibitory (hM4), or the mCherry tag only targeted to DA neurons in the vPAG and dorsal raphe (Fig. 2A). Immunohistochemistry demonstrated robust DREADD expression restricted to the vPAG and dorsal raphe that colocalized with neurons expressing tyrosine hydroxylase (Fig. 2B,D). We observed $61 \pm 10\%$ of green-labeled TH neurons in the vPAG and dorsal raphe colocalized with mcherry-labeled neurons expressing DAT protein, and $84 \pm 8\%$ of mcherry-labeled DAT cre-expressing neurons colocalized with green-labeled TH containing neurons (Fig. 2C).

As shown in Figure 2E, there was no change in thermal sensitivity (paw withdrawal latency; -0.85 s, 95% CI $[-1.84, 0.68$ s], paired t test, df_7 , $p = 0.0363$) nor in mechanical allodynia (Fig. 2F; paw withdrawal thresholds; 0 g, 95% CI $[0, 0.22$ g]), Wilcoxon signed rank, df_7 , $p = 0.25$) in mCherry control mice before and after injection with CNO. CNO activation of vPAG DA neurons (hM3, $n = 9$) reduced both the thermal (9.81 s, 95% CI $[6.39, 12.10$ s], paired t test, df_8 , $p < 0.0001$) and mechanical sensitivity (0.44 g, 95% CI $[0.16, 0.72$ g]), Wilcoxon signed rank, df_8 , $p = 0.0313$) in DAT-cre mice, while inhibition (hM4, $n = 8$) caused a significant increase in both thermal (-5.96 s, 95% CI $[-6.37, -5.48$ s], paired t test, df_7 , $p < 0.0001$) and mechanical sensitivity (-0.29 g, 95% CI $[-0.53, -0.18$ g]), Wilcoxon signed rank, df_7 , $p = 0.0078$).

A separate group of animals was prepared for functional characterization of the hM3 and hM4 DREADDs. Three weeks after DREADD injection, acute coronal slices of the vPAG/dorsal raphe ($n = 4$) were obtained from each group and were prepared for whole cell recordings to demonstrate fidelity of the expressed receptors. hM3-expressing vPAG/dorsal raphe neurons were held at hyperpolarized membrane potentials and then were exposed to a bath application of $10 \mu\text{M}$ CNO (Fig. 3A). This caused a transient depolarization and robust action potential firing in both vGlut2 (3.7 Hz, 95% CI $[1.2, 6.4$ Hz]) and DAT expressing neurons (2.6 Hz, 95% CI $[1.0, 7.0$ Hz]). Neuronal inhibition by hM4Di was measured by first holding the cells with a depolarizing current, which elicited persistent action potential firing in both DAT and vGlut2

neurons, and then perfusing the bath with $10 \mu\text{M}$ CNO (Fig. 3B). This resulted in prolonged membrane hyperpolarization and decreased firing of both vGlut2 (0.2 Hz, 95% CI $[0, 0.3$ Hz]) and DAT expressing neurons (0.2 Hz, 95% CI $[0.1, 0.3$ Hz]; Fig. 3C). CNO significantly depolarized hM3Dq-expressing vGlut2 (Δ membrane potential 17.3 mV, 95% CI $[6.8, 30.0$ mV], $p < 0.05$) and DAT neurons (Δ membrane potential 20.6 mV, 95% CI $[5.9, 45.2$ mV], $p < 0.05$), while significantly hyperpolarizing hM4Di-expressing vGlut2 (Δ membrane potential -8.0 mV, 95% CI $[-12.8, -6.3$ mV], $p < 0.05$) and DAT containing neurons (Δ membrane potential -5.3 mV, 95% CI $[-8.5, -3.9$ mV], $p < 0.05$; Fig. 3D).

Interestingly, while levels of antinociception were significant and quantitatively similar when DA and glutamate neurons in the vPAG/dorsal raphe were selectively stimulated, it was clear that the animals' behavior was noticeably different. Activation of glutamatergic neurons in the vPAG reliably triggered strong freezing behavior after administration of CNO, whereas activation of dopaminergic neurons did not. To quantify these differences in behavior, mice were exposed to a novel context under low-fear conditions, and had the level of anxiety in an open field test, and preferential exploration of a light area rather than a dark area, evaluated after selective stimulation of glutamatergic and dopaminergic vPAG/dorsal raphe neurons.

As shown in Figure 4A, CNO activation of glutamatergic vPAG/dorsal raphe neurons (hM3, $n = 8$) produced behaviors consistent with anxiety including decreased distance traveled (from 13.3 m, 95% CI $[9.0-17.6$ m] in the control, to 5.3 m, 95% CI $[1.4-9.3$ m] in hM3, ANOVA with Dunnett's, df_7 , $p = 0.0036$), travel velocity (from 0.044 m/s, 95% CI $[0.03-0.058$ m/s] in the control, to 0.018 m/s, 95% CI $[0.005-0.031$ m/s] in hM3, ANOVA with Dunnett's, df_7 , $p = 0.0037$), and time spent in the center of the open field (from 19.7 s, 95% CI $[1.5-37.9$ s] in the control, to 0.5 s, 95% CI $[-0.1-1.2$ s] in hM3, Kruskal-Wallis with Dunn's, df_7 , $p = 0.014$) as well as increased freezing time (from 109.8 s, 95% CI $[41.3-178.3$ s] in the control, to 270.3 s, 95% CI $[254.3-286.2$ s] in hM3, ANOVA with Dunnett's, df_7 , $p = 0.0001$). CNO inhibition of glutamatergic vPAG/dorsal raphe neurons (hM4, $n = 8$) had no effect on these end points (11.4 m, 95% CI $[8.5-14.4$ m], ANOVA with Dunnett's, df_7 , $p = 0.624$; 0.038 m/s, 95% CI $[0.028-0.048$ m/s], ANOVA with Dunnett's, df_7 , $p = 0.658$; 14.8 s, 95% CI $[5.1-24.5$ s], Kruskal-Wallis with Dunn's, df_7 , $p > 0.999$; 109.4 s, 95% CI $[82.9-135.9$ s], ANOVA with Dunnett's, df_7 , $p = 0.9997$). DREADD activation or inhibition of dopaminergic vPAG/dorsal raphe neurons (hM3, $n = 8$) also had no effect on distance traveled, travel velocity, center time or freezing time (distance traveled: 15.9 m, 95% CI $[12.6-19.2$ m] control, 17.8 m, 95% CI $[14.9-20.7$ m] hM3, 18.8 m, 95% CI $[14.6-23.0$ m] hM4, ANOVA, df_7 , $p = 0.39$; travel velocity: 0.053 m/s, 95% CI $[0.042-0.064$ m/s] control, 0.059 m/s, 95% CI $[0.050-0.069$ m/s] in




Figure 2. Dopaminergic neurons in the vPAG produce antinociception. **A**, Dopaminergic neurons were targeted by local vPAG injection DREADD containing AAV into transgenic mice expressing Cre under control of the DA transporter gene (DAT-cre). **B**, DREADDs expression in the vPAG/dorsal raphe of DAT-cre mice (immunohistochemistry). **C**, 61 ± 10% of green-labeled TH neurons in the vPAG and dorsal raphe colocalized with mcherry-labeled neurons expressing DAT protein, and 84 ± 8% of mcherry-labeled DAT cre-expressing neurons colocalized with green-labeled TH containing neurons. **D**, DREADDs are expressed in vPAG/dorsal raphe TH⁺ neurons as demonstrated by colocalized expression in the merged image. **E, F**, Bar graphs represent the median value of the data, while the error bars are the 95% CI. White bars indicate nociceptive testing before intraperitoneal CNO injections while green bars indicate nociceptive testing 1 h after CNO administration. Pair-wise comparisons with a Wilcoxon signed-rank test indicated no significant behavioral difference in mcherry animals ($n = 8$) after CNO treatment. CNO activation of vPAG DA neurons (hM3, $n = 9$) produced analgesia, with increased paw withdrawal latencies to both thermal (paired t test, $df8$, $p < 0.0001$) and

continued

mechanical stimuli (Wilcoxon signed rank, $df8$, $p = 0.0313$) in DAT-cre mice, while inhibition (hM4, $n = 8$) caused a significant decrease in paw withdrawal latencies to both thermal (paired t test, $df7$, $p < 0.0001$) and mechanical stimuli (Wilcoxon signed rank, $df7$, $p = 0.0078$). * $p < 0.05$.

hM3, 0.063 m/s, 95% CI [0.049–0.077 m/s] in hM4, ANOVA, $df7$, $p = 0.40$; time in the center: 23.0 s, 95% CI [11.9–34.1 s] control, 22.5 s, 95% CI [14.4–30.7 s] hM3, 17.5 s, 95% CI [11.8–23.1 s] hM4, ANOVA, $df7$, $p = 0.52$; freezing time: 98.9 s, 95% CI [68.9–128.9 s] control, 85.2 s, 95% CI [65.03–105.4 s] hM3, 90.5 s, 95% CI [62.6–118.4 s] hM4, ANOVA, $df7$, $p = 0.68$).

In the light/dark test, activation of vPAG/dorsal raphe glutamatergic neurons lead to decreased distance traveled (from 4.6 m, 95% CI [2.2–7.0 m] in the control, to 0.3 m, 95% CI [–0.4–0.9 m] in hM3, Kruskal–Wallis with Dunn’s, $df7$, $p = 0.0009$), travel velocity (from 0.062 m/s, 95% CI [0.048–0.077 m/s] in the control, to 0.003 m/s, 95% CI [–0.004–0.009 m/s] in hM3, Kruskal–Wallis with Dunn’s, $df7$, $p < 0.0001$) and time spent in the light side of the chamber (from 72.3 s, 95% CI [37.7–106.9 s] in the control, to 9.5 s, 95% CI [–9.7–28.7 s] in hM3, Kruskal–Wallis with Dunn’s, $df7$, $p = 0.011$) as well as increased time spent in the dark, enclosed side of the chamber (from 227.7 s, 95% CI [193.1–262.3 s] in the control, to 290.5 s,

95% CI [271.3–309.7 s] in hM3, Kruskal–Wallis with Dunn’s, $df7$, $p = 0.011$) as show in Figure 4B. CNO inhibition of glutamatergic vPAG/dorsal raphe neurons (hM4, $n = 8$) had no effect on these end points (3.1 m, 95% CI [1.8–4.4 m], Kruskal–Wallis with Dunn’s, $df7$, $p = 0.890$; 0.039 m/s, 95% CI [0.031–0.048 m/s], Kruskal–Wallis with Dunn’s, $df7$, $p = 0.0974$; 84.2 s, 95% CI [26.6–141.7 s], Kruskal–Wallis with Dunn’s, $df7$, $p > 0.999$; 215.9 s, 95% CI [158.3–273.4 s], Kruskal–Wallis with Dunn’s, $df7$, $p > 0.999$). DREADD activation or inhibition of dopaminergic vPAG/dorsal raphe neurons (hM3, $n = 8$) also had no effect on distance traveled, travel velocity, or time spent on the light side of the enclosure nor on time spent in the dark, enclosed side (distance traveled: 4.4 m, 95% CI [1.5–7.3 m] control, 5.8 m, 95% CI [4.7–6.9 m] hM3, 5.2 m, 95% CI [3.5–6.9 m] hM4, Kruskal–Wallis, $df7$, $p = 0.475$; travel velocity: 0.05 m/s, 95% CI [0.022–0.078 m/s] control, 0.055 m/s, 95% CI [0.047–0.063 m/s] in hM3, 0.052 m/s, 95% CI [0.044–0.059 m/s] in hM4, ANOVA, $df7$, $p = 0.885$; time in the





Figure 3. Functional characterization of hM3 and hM4 DREADDs in vPAG/dorsal raphe neurons of vGglut2-Cre and DAT-cre mice. **A**, Whole-cell current-clamp recording from an hM3Dq-expressing vPAG neuron. Brief bath application of 10 μ M CNO (red box) caused a transient depolarization and robust action potential firing in both vGlut2 and DAT neurons. Blue lines represent individual spike events. These were then aggregated into 5-s bins and the frequency plotted as shown in the green histogram. **B**, Voltage trace showing that bath perfusion with 10 μ M CNO caused prolonged membrane hyperpolarization and silencing of both vGlut and DAT vPAG/dorsal raphe neurons. **C**, Quantification of the CNO effects on neuron firing rate in grouped vGlut2 and DAT neurons ($n = 4$). **D**, Quantification of the CNO effects on membrane potential (all values are mean \pm SEM; * $p < 0.05$).

A Open Field Test



B Light/Dark Test




Figure 4. Glutamatergic neurons in the vIPAG drive fear responses, as assessed using open field and light/dark behavioral tests (mCherry = controls, hM3 = excitatory DREADD, hM4 = inhibitory DREADD). **A**, Open field test. DREADD activation (hM3, $n = 8$) of vIPAG glutamate neurons in *vglut-2-cre* mice produced decrease in distance traveled, velocity of travel, and time spent in the center of an open field along with increase in the time spent frozen when compared with control mice, while inhibition (hM4, $n = 8$) had no effect on these endpoints (ANOVA with Dunnett’s multiple comparison test, $*p < 0.05$, $**p < 0.001$). In contrast, DREADD activation (hM3, $n = 8$) or inhibition (hM4, $n = 8$) of dopaminergic vIPAG/dorsal raphe neurons in *DAT-cre* mice had no effect on distance traveled, travel velocity, center time, or freezing time (one-way ANOVA). **B**, In the light/dark test, DREADD activation (hM3, $n = 8$) of vIPAG/dorsal raphe glutamatergic neurons lead to decreased distance traveled, travel velocity, and time spent in the light side of the chamber as well as increased time spent in the dark, enclosed side of the chamber (Kruskal–Wallis with Dunn’s multiple comparison test, $*p < 0.05$, $**p < 0.001$). CNO inhibition of glutamatergic vIPAG/dorsal raphe neurons (hM4, $n = 8$) had no effect on these endpoints. In contrast, DREADD activation or inhibition of dopaminergic vIPAG/dorsal raphe neurons (hM3, $n = 8$) also had no effect on

continued

distance traveled, travel velocity, or time spent on the light side of the enclosure nor on time spent in the dark, enclosed side (Kruskal–Wallis).

light: 78.2 s, 95% CI [45.5–110.8 s] control, 104.4 s, 95% CI [91.4–117.4 s] hM3, 100.5 s, 95% CI [66.9 to 134 s] hM4, Kruskal–Wallis, $df7$, $p = 0.271$; time in the dark: 221.8 s, 95% CI [189.2–254.5 s] control, 195.6 s, 95% CI [182.6–208.7 s] hM3, 199.6 s, 95% CI [166–233.1 s] hM4, Kruskal–Wallis, $df7$, $p = 0.271$).

In summary, vGlut2-cre animals consistently showed higher indices of anxiety, with increased freezing time and more time spent in the safety of the dark area when administered CNO, suggesting that vIPAG glutamatergic neuron activation mediated the anxiogenic effect. In contrast, DAT-cre mice with hM3 DREADD expression in the vIPAG/dorsal raphe failed to show anxiety behavior when administered CNO, suggesting that activation of DA neurons in this region is analgesic without being anxiogenic.

To determine the receptors mediating the vIPAG/dorsal raphe dopaminergic antinociceptive effect, subtype selective DA receptor antagonists were administered systemically. Pretreatment with the selective D1 receptor antagonist SCH-23390 (0.5 mg/kg; 4.94 s, 95% CI [3.85, 9.57 s], paired t test, $df8$, $p < 0.0001$) or the selective D2 receptor antagonist raclopride (5 mg/kg; 1.15 s, 95% CI [3.35, 8.53 s], paired t test, $df8$, $p = 0.0176$) failed to prevent the increase in paw withdrawal latency exhibited by CNO activation of vIPAG DA neurons (9.81 s, 95% CI [6.39, 12.10 s], paired t test, $df8$, $p < 0.0001$). In contrast, the nonspecific DA receptor antagonist haloperidol (0.3 mg/kg; -0.20 s, 95% CI [-0.44 , 0.21 s]) was effective in blocking the antinociceptive effect, resulting in no significant difference in paw withdrawal latency from baseline (paired t test, $df8$, $p = 0.413$; Fig. 5A). The results were similar when mice were exposed to a mechanical nociceptive stimulus (Fig. 5B), with only haloperidol effectively preventing vIPAG DA neuron-mediated antinociception (-0.24 g, 95% CI [-0.32 , 0.08 g], Wilcoxon signed rank, $p = 0.371$). However, treatment with SCH-23390 (0.5 mg/kg; 0.44 g, 95% CI [0.29, 0.62 g], Wilcoxon signed rank, $df7$, $p = 0.0078$) or raclopride (0.5 mg/kg; 0.24 g, 95% CI [0.13, 0.50 g], Wilcoxon signed rank, $df7$, $p = 0.0313$) had no effect on the CNO-mediated increase in paw withdrawal threshold (0.44 g, 95% CI [0.16, 0.72 g]).

Finally, carrageenan was injected into the hind paw of DAT-cre mice as a model for inflammatory pain to determine whether the antinociceptive effect of vIPAG DA activation was potent enough to inhibit persistent pain. Figure 6A shows the characteristic decrease in paw withdrawal thermal threshold in the carrageenan-treated hind paw, which reached steady state ~ 3 h after injection. Baseline measurements were made before carrageenan hind paw injection. Three hours later, mice received intraperitoneal CNO injection followed, an hour later, by paw withdrawal latency measurements (Fig. 6B). Control mice who expressed mcherry but lacked DREADDs demonstrated a significant decrease in withdrawal latencies in the carrageenan-treated paw compared with the uninflamed paw (-6.13 s, 95% CI [-6.53 , -5.45 s], paired t

test, $df6$, $p < 0.0001$; Fig. 6C), and CNO administration did not produce any effect (-5.49 s, 95% CI [-7.02 , -5.01 s], paired t test, $df6$, $p < 0.0001$). However, CNO activation of vIPAG DA neurons in mice expressing hM3 DREADDs induced an analgesic effect, significantly increasing the paw withdrawal latency of the carrageenan-inflamed paw (1.3 s, 95% CI [0, 2.16 s], paired t test, $df8$, $p = 0.0115$), indicating that activation of vIPAG DA neurons was sufficient to inhibit persistent inflammatory pain.


Discussion

Here, we report that chemogenetic activation of vIPAG glutamatergic or dopaminergic neurons significantly attenuates both thermal and mechanical nociception, and that dopaminergic antinociception is prevented by the nonspecific DA receptor antagonist haloperidol. In addition, inhibiting either glutamatergic or dopaminergic neurons causes thermal and mechanical hypersensitivity. Despite similar antinociceptive effects, activating vIPAG glutamatergic neurons induced fear behaviors such as increased freezing time in the open field test and decreased light area exploration in the light/dark test, while there was no increase in fear behaviors with chemoactivation of vIPAG dopaminergic neurons. Finally, vIPAG DA neuron activation was sufficient to inhibit the persistent nociception caused by carrageenan-induced inflammation. These results demonstrate that there is a way to separate the generation of analgesia from anxiety when targeting the vIPAG, by selectively targeting DA neurons.

The antinociceptive and anxiogenic effects of vIPAG glutamatergic neurons have been studied for many years (Bandler et al., 1985; Bandler and Carrive, 1988; Jacquet, 1988; Jones and Gebhart, 1988; Jensen and Yaksh, 1989; Carstens et al., 1990; Tovote et al., 2016; Samineni et al., 2017). However, it was only recently that an amygdala-PAG-medullary circuit responsible for generating freezing behavior was elucidated (Tovote et al., 2016). A subpopulation of vIPAG glutamatergic neurons project to premotor cells located in the magnocellular nucleus (Mc) of the medulla and cause freezing when excited. Disinhibition of this vIPAG→Mc pathway occurs by way of a disynaptic GABAergic micro-circuit receiving inhibitory input from CEA. The CEA sends GABAergic projections to the vIPAG that preferentially target vIPAG GABAergic cells. These vIPAG GABAergic interneurons integrate multiple inhibitory and excitatory inputs and help to regulate the selection of either freezing or flight behaviors. Specifically, inhibition of the vIPAG GABAergic cells by GABAergic CEA inputs causes excitation of the vIPAG glutamatergic neurons that project to the Mc and produce passive, freezing behavior. In contrast, excitation by glutamatergic inputs from the dIPAG inhibits the projections to the Mc causing the animals to exhibit active, flight behavior.

Global activation of vIPAG glutamate neurons, as was achieved in the present study, also produces antinocice-

A Heargreaves Test: Thermal Hyperalgesia



B Von Frey Test: Mechanical allodynia





Figure 5. Haloperidol inhibits vIPAG dopaminergic neuron mediated analgesia. **A, B,** Changes in paw withdrawal latencies to a thermal test were significant (one-way ANOVA, $p < 0.0001$) as were changes in paw retraction force (Kruskal–Wallis, $p < 0.0001$). Pair-wise comparisons indicated that only the nonspecific DA receptor antagonist haloperidol (0.3 mg/kg) prevented the analgesia induced by activation of vIPAG DA neurons by CNO (1 mg/kg), as paw withdrawal latencies (paired t test, $p = 0.413$) and retraction forces (Wilcoxon signed rank, $p = 0.371$) showed no significant change from baseline. In contrast, treatment with the selective D1 receptor antagonist SCH-23390 (0.5 mg/kg) or the selective D2 receptor antagonist raclopride (0.5 mg/kg) were ineffective in preventing the analgesia. * $p < 0.05$.


ption. However, as demonstrated by [Tovote et al. \(2016\)](#), there was no antinociceptive effect when excitation was restricted to the subpopulation of glutamate neurons projecting to the Mc, suggesting that another glutamatergic circuit is mediating the antinociceptive effects. Based on pharmacologic studies, a glutamatergic pathway appears to connect the vIPAG with the RVM and is directed at RVM OFF-cells specifically. Activation of these cells by morphine administration or any other means produces antinociception ([Tortorici and Morgan, 2002](#); [Morgan et al., 2008](#)). These results strongly suggest that subpopulations of glutamatergic neurons within the vIPAG exert different effects based on the anatomic location of their projections.

We chose to use the known antinociceptive and angiogenic effects of vIPAG glutamatergic activation as a positive control to compare and contrast the new observation that vIPAG/dorsal raphe dopaminergic neurons produce antinociceptive without angiogenic behavioral effects. In contrast to vIPAG glutamatergic neurons, vIPAG dopaminergic neurons do not project to the RVM. Instead, they project up to the ventral tegmental area (VTA), the nucleus accumbens (NAc), the BNST, and CEA ([Li et al., 2016](#)). Recent studies demonstrate that direct VTA DA neuron stimulation attenuates neuropathic allodynia and activates exercise induced hypoalgesia ([Kami et al., 2018](#); [Watanabe et al., 2018](#)). Therefore, vIPAG/dorsal raphe DA neurons may be exerting their antinociceptive effects by

A Time course of carrageenan-induced thermal hyperalgesia



B



C Thermal nociception




Figure 6. Effect of vPAG dopaminergic neuron activation on carrageenan-induced thermal sensitivity. **A**, A stable and significant reduction in paw withdrawal time to a thermal stimulus was achieved 180 min following carrageenan injection into the left hind paw of DAT-cre mice. **B**, Pre-carrageenan paw withdrawal latencies were measured to obtain a baseline. Three hours after carrageenan injection, experimental and control mice received intraperitoneal CNO injections. One hour later, paw withdrawal latencies were recorded for the inflamed and control paws. **C**, In mice expressing the hM3Dq DREADDs (hM3), CNO activation of vPAG DA neurons produced an analgesic effect by significantly increasing the paw withdrawal latency of the carrageenan-inflamed paw (†, paired *t* test, *df*8, *p* = 0.0115). **p* < 0.05.

modulating DA levels in the VTA and NAc, rather than working through the classic descending inhibition pathway. Our studies also suggest the vPAG/dorsal raphe neurons do not directly interact with the amygdala-PAG-medullary circuit, as these animals failed to show anxiogenic behavioral effects. Studies have been conducted to elucidate the electrophysiologic effect of GABA neurons on vPAG/DA function. However, no study has yet investigated the local microcircuit effects that these DA neurons exert within the PAG.

It is well known that VTA DA neurons are an essential part of the circuit mediating locomotion, and it has been demonstrated that chemogenetic activation of VTA DA neurons increases distances traveled in the open field test (Wang et al., 2013; Boekhoudt et al., 2016). However,

vPAG/dorsal raphe DA neurons do not appear to affect locomotion, as chemogenetic activation of vPAG DA neurons failed to increase the distance traveled in the open field test, both in the present study as well as in studies by others (Li et al., 2016), suggesting that the decrease in freezing time and activity in the light/dark tests can be attributed to effects on anxiety behaviors rather than on movement directly.

Previous attempts to characterize the analgesic efficacy of vPAG DA neurons stimulation have used acute, episodic pain stimuli including measuring hot plate latency and the tail flick test (Flores et al., 2004; Meyer et al., 2009; Li et al., 2016). In addition to acute, episodic pain, we have demonstrated that the analgesic effect is sufficient to decrease persistent inflammatory pain as well.

However, additional studies are needed to determine whether the antinociception produced by activation of vPAG DA neurons is sufficient to treat other forms of chronic pain, including neuropathic and cancer pain.

In this regard, while the use of chemogenetic or optogenetic techniques are not currently available as clinical treatments, the observation that selective DA neurons activation provides analgesia could be clinically significant. DA agonists and stimulants are commonly used in the treatment of Parkinson's disease and attention deficit disorder, but are not currently used for the relief of pain. Pre-clinical studies in rodents suggest that DA agonists and psychostimulants such as D-amphetamine and methylphenidate (MPH), are effective analgesics and provide synergistic effects with opioids. Several groups have demonstrated that (1) DA agonists produce analgesia alone (Dennis and Melzack, 1983; Lin et al., 1989; Morgan and Franklin, 1990); (2) when combined with opioids, DA agonists potentiate opioid analgesia (Burrill et al., 1944; Goetzl et al., 1944; Ivy et al., 1944); (3) opioid analgesia is in part mediated through the actions of DA (Morgan and Franklin, 1991); (4) both D₁ and D₂ receptors are involved in the effect (Morgan and Franklin, 1991; Flores et al., 2004; Meyer et al., 2009); (5) the VTA contributes to both the rewarding and analgesic actions of DA (Morgan and Franklin, 1990; Matsui et al., 2014; Schifirneț et al., 2014; Fields and Margolis, 2015; Trang et al., 2015); and (6) DA neurons in the ventral PAG play key roles in DA-mediated analgesia (Flores et al., 2004; Meyer et al., 2009; Chiou et al., 2013).

While we specifically targeted DA transporter-containing neurons, midbrain DA neurons have been shown to co-release neurotransmitters such as GABA or glutamate (Hnasko et al., 2010; Stuber et al., 2010; Tecuapetla et al., 2010; Tritsch et al., 2012; Li et al., 2016). It is therefore possible that the behavioral effects may not be purely DA mediated. To gain insight into this question, antagonists selective for DA receptor subtypes were given systemically to block the analgesic response. Previous studies showed conflicting results with regards to which DA receptor mediated PAG analgesic effects; one study suggested it was through D1 receptors (Flores et al., 2004) while another showed that D2 receptors were crucial (Meyer et al., 2009). In the current experiments, the antinociception produced by vPAG DA neuron stimulation was incompletely prevented by selective blockade of DA D1 receptor or D2 receptor, and completely prevented by the non-specific DA receptor antagonist haloperidol, suggesting that both receptors may contribute to the antinociceptive effect.

Here, we show that selective stimulation of DA neurons within the vPAG/dorsal raphe produced antinociception without anxiety, and further characterized a novel analgesic target, as there are no medications used clinically which specifically target dopaminergic circuits for the relief of pain.

References

- Bandler R, Carrive P (1988) Integrated defence reaction elicited by excitatory amino acid microinjection in the midbrain periaqueductal grey region of the unrestrained cat. *Brain Res* 439:95–106. [CrossRef Medline](#)
- Bandler R, Depaulis A, Vergnes M (1985) Identification of midbrain neurones mediating defensive behaviour in the rat by microinjections of excitatory amino acids. *Behav Brain Res* 15:107–119. [CrossRef Medline](#)
- Behbehani MM (1995) Functional characteristics of the midbrain periaqueductal gray. *Prog Neurobiol* 46:575–605. [CrossRef Medline](#)
- Beitz AJ (1990) Relationship of glutamate and aspartate to the periaqueductal gray-raphe magnus projection: analysis using immunocytochemistry and microdialysis. *J Histochem Cytochem* 38:1755–1765. [CrossRef Medline](#)
- Bittar RG, Kar-Purkayastha I, Owen SL, Bear RE, Green A, Wang S, Aziz TZ (2005) Deep brain stimulation for pain relief: a meta-analysis. *J Clin Neurosci* 12:515–519. [CrossRef Medline](#)
- Boekhoudt L, Omrani A, Luijendijk MC, Wolterink-Donselaar IG, Wijbrans EC, van der Plasse G, Adan RA (2016) Chemogenetic activation of dopamine neurons in the ventral tegmental area, but not substantia nigra, induces hyperactivity in rats. *Eur Neuropsychopharmacol* 26:1784–1793. [CrossRef Medline](#)
- Burrill DY, Goetzl FR, Ivy AC (1944) The pain threshold raising effects of amphetamine. *J Dent Res* 23:337–344. [CrossRef](#)
- Carstens E, Hartung M, Stelzer B, Zimmermann M (1990) Suppression of a hind limb flexion withdrawal reflex by microinjection of glutamate or morphine into the periaqueductal gray in the rat. *Pain* 43:105–112. [CrossRef Medline](#)
- Chiou RJ, Chang CW, Kuo CC (2013) Involvement of the periaqueductal gray in the effect of motor cortex stimulation. *Brain Res* 1500:28–35. [CrossRef Medline](#)
- Dennis SG, Melzack R (1983) Effects of cholinergic and dopaminergic agents on pain and morphine analgesia measured by three pain tests. *Exp Neurol* 81:167–176. [CrossRef Medline](#)
- Falconi-Sobrinho LL, Anjos-Garcia TD, Elias-Filho DH, Coimbra NC (2017) Unravelling cortico-hypothalamic pathways regulating unconditioned fear-induced antinociception and defensive behaviours. *Neuropharmacology* 113:367–385. [CrossRef Medline](#)
- Fardin V, Oliveras JL, Besson JM (1984) A reinvestigation of the analgesic effects induced by stimulation of the periaqueductal gray matter in the rat. II. Differential characteristics of the analgesia induced by ventral and dorsal PAG stimulation. *Brain Res* 306:125–139. [CrossRef Medline](#)
- Fields HL, Margolis EB (2015) Understanding opioid reward. *Trends Neurosci* 38:217–225. [CrossRef Medline](#)
- Flores JA, El Banoua F, Galán-Rodríguez B, Fernandez-Espejo E (2004) Opiate anti-nociception is attenuated following lesion of large dopamine neurons of the periaqueductal grey: critical role for D1 (not D2) dopamine receptors. *Pain* 110:205–214. [CrossRef Medline](#)
- Goetzl FR, Burrill DY, Ivy AC (1944) The analgesic effect of morphine alone and in combination with dextroamphetamine. *Proc Soc Exper Biol Med* 55:248–250. [CrossRef](#)
- Gomez JL, Bonaventura J, Lesniak W, Mathews WB, Sysa-Shah P, Rodriguez LA, Ellis RJ, Richie CT, Harvey BK, Dannals RF, Pomper MG, Bonci A, Michaelides M (2017) Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. *Science* 357:503–507. [CrossRef Medline](#)
- Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. *Pain* 32:77–88. [CrossRef Medline](#)
- Hnasko TS, Chuhma N, Zhang H, Goh GY, Sulzer D, Palmiter RD, Rayport S, Edwards RH (2010) Vesicular glutamate transport promotes dopamine storage and glutamate corelease in vivo. *Neuron* 65:643–656. [CrossRef Medline](#)
- Hosobuchi Y, Adams JE, Linchitz R (1977) Pain relief by electrical stimulation of the central gray matter in humans and its reversal by naloxone. *Science* 197:183–186. [Medline](#)
- Ivy AC, Goetzl FR, Burrill DY (1944) Morphine-dextroamphetamine analgesia. *War Med* 6:67–71.

- Jacquet YF (1988) The NMDA receptor: central role in pain inhibition in rat periaqueductal gray. *Eur J Pharmacol* 154:271–276. [CrossRef](#) [Medline](#)
- Jacquet YF, Lajtha A (1974) Paradoxical effects after microinjection of morphine in the periaqueductal gray matter in the rat. *Science* 185:1055–1057. [CrossRef](#) [Medline](#)
- Jensen TS, Yaksh TL (1989) Comparison of the antinociceptive effect of morphine and glutamate at coincidental sites in the periaqueductal gray and medial medulla in rats. *Brain Res* 476:1–9. [CrossRef](#) [Medline](#)
- Jones SL, Gebhart GF (1988) Inhibition of spinal nociceptive transmission from the midbrain, pons and medulla in the rat: activation of descending inhibition by morphine, glutamate and electrical stimulation. *Brain Res* 460:281–296. [CrossRef](#) [Medline](#)
- Kami K, Tajima F, Senba E (2018) Activation of mesolimbic reward system via laterodorsal tegmental nucleus and hypothalamus in exercise-induced hypoalgesia. *Sci Rep* 8:11540. [CrossRef](#) [Medline](#)
- Kim EJ, Horovitz O, Pellman BA, Tan LM, Li Q, Richter-Levin G, Kim JJ (2013) Dorsal periaqueductal gray-amygdala pathway conveys both innate and learned fear responses in rats. *Proc Natl Acad Sci USA* 110:14795–14800. [CrossRef](#) [Medline](#)
- Li C, Sugam JA, Lowery-Gionta EG, McElligott ZA, McCall NM, Lopez AJ, McKlveen JM, Pleil KE, Kash TL (2016) Mu opioid receptor modulation of dopamine neurons in the periaqueductal gray/dorsal raphe: a role in regulation of pain. *Neuropsychopharmacology* 41:2122–2132. [CrossRef](#) [Medline](#)
- Lin Y, Morrow TJ, Kiritsy-Roy JA, Terry LC, Casey KL (1989) Cocaine: evidence for supraspinal, dopamine-mediated, non-opiate analgesia. *Brain Res* 479:306–312. [CrossRef](#) [Medline](#)
- Matsui A, Jarvie BC, Robinson BG, Hentges ST, Williams JT (2014) Separate GABA afferents to dopamine neurons mediate acute action of opioids, development of tolerance, and expression of withdrawal. *Neuron* 82:1346–1356. [CrossRef](#) [Medline](#)
- Meyer PJ, Morgan MM, Kozell LB, Ingram SL (2009) Contribution of dopamine receptors to periaqueductal gray-mediated antinociception. *Psychopharmacology (Berl)* 204:531–540. [CrossRef](#) [Medline](#)
- Miguel TT, Nunes-de-Souza RL (2006) Defensive-like behaviors and antinociception induced by NMDA injection into the periaqueductal gray of mice depend on nitric oxide synthesis. *Brain Res* 1076:42–48. [CrossRef](#) [Medline](#)
- Millan MJ (2002) Descending control of pain. *Prog Neurobiol* 66:355–474. [CrossRef](#) [Medline](#)
- Morgan MJ, Franklin KB (1990) 6-Hydroxydopamine lesions of the ventral tegmentum abolish D-amphetamine and morphine analgesia in the formalin test but not in the tail flick test. *Brain Res* 519:144–149. [CrossRef](#) [Medline](#)
- Morgan MJ, Franklin KB (1991) Dopamine receptor subtypes and formalin test analgesia. *Pharmacol Biochem Behav* 40:317–322. [CrossRef](#) [Medline](#)
- Morgan MM, Whitney PK, Gold MS (1998) Immobility and flight associated with antinociception produced by activation of the ventral and lateral/dorsal regions of the rat periaqueductal gray. *Brain Res* 804:159–166. [CrossRef](#) [Medline](#)
- Morgan MM, Whittier KL, Hegarty DM, Aicher SA (2008) Periaqueductal gray neurons project to spinally projecting GABAergic neurons in the rostral ventromedial medulla. *Pain* 140:376–386. [CrossRef](#) [Medline](#)
- Paxinos G, Franklin KBJ, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates, Ed 2. San Diego: Academic Press.
- Reichling DB, Basbaum AI (1990) Contribution of brainstem GABAergic circuitry to descending antinociceptive controls: II. Electron microscopic immunocytochemical evidence of GABAergic control over the projection from the periaqueductal gray to the nucleus raphe magnus in the rat. *J Comp Neurol* 302:378–393. [CrossRef](#) [Medline](#)
- Reynolds DV (1969) Surgery in the rat during electrical analgesia induced by focal brain stimulation. *Science* 164:444–445. [CrossRef](#) [Medline](#)
- Richardson DE, Akil H (1977) Pain reduction by electrical brain stimulation in man. Part 1: acute administration in periaqueductal and periventricular sites. *J Neurosurg* 47:178–183. [CrossRef](#) [Medline](#)
- Samineni VK, Grajales-Reyes JG, Copits BA, O'Brien DE, Trigg SL, Gomez AM, Bruchas MR, Gereau RW 4th (2017) Divergent modulation of nociception by glutamatergic and GABAergic neuronal subpopulations in the periaqueductal gray. *eNeuro* 4:ENEURO.0129-16.2017. [CrossRef](#) [Medline](#)
- Schifirneț E, Bowen SE, Borszcz GS (2014) Separating analgesia from reward within the ventral tegmental area. *Neuroscience* 263:72–87. [CrossRef](#) [Medline](#)
- Schoo SM, Bobeck EN, Morgan MM (2017) Enhanced antinociception with repeated microinjections of apomorphine into the periaqueductal gray of male and female rats. *Behav Pharmacol* 29:234–240. [CrossRef](#) [Medline](#)
- Shapira NA, Okun MS, Wint D, Foote KD, Byars JA, Bowers D, Springer US, Lang PJ, Greenberg BD, Haber SN, Goodman WK (2006) Panic and fear induced by deep brain stimulation. *J Neurol Neurosurg Psychiatry* 77:410–412. [CrossRef](#) [Medline](#)
- Stuber GD, Hnasko TS, Britt JP, Edwards RH, Bonci A (2010) Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate. *J Neurosci* 30:8229–8233. [CrossRef](#) [Medline](#)
- Suckow SK, Deichsel EL, Ingram SL, Morgan MM, Aicher SA (2013) Columnar distribution of catecholaminergic neurons in the ventrolateral periaqueductal gray and their relationship to efferent pathways. *Synapse* 67:94–108. [CrossRef](#) [Medline](#)
- Tecuapetla F, Patel JC, Xenias H, English D, Tadros I, Shah F, Berlin J, Deisseroth K, Rice ME, Tepper JM, Koos T (2010) Glutamatergic signaling by mesolimbic dopamine neurons in the nucleus accumbens. *J Neurosci* 30:7105–7110. [CrossRef](#) [Medline](#)
- Tomaz C, Brandão M, Bagri A, Carrive P, Schmitt P (1988) Flight behavior induced by microinjection of GABA antagonists into periventricular structures in detelencephalated rats. *Pharmacol Biochem Behav* 30:337–342. [CrossRef](#) [Medline](#)
- Tortorici V, Morgan MM (2002) Comparison of morphine and kainic acid microinjections into identical PAG sites on the activity of RVM neurons. *J Neurophysiol* 88:1707–1715. [CrossRef](#) [Medline](#)
- Tovote P, Esposito MS, Botta P, Chaudun F, Fadok JP, Markovic M, Wolff SB, Ramakrishnan C, Fenno L, Deisseroth K, Herry C, Arber S, Lüthi A (2016) Midbrain circuits for defensive behaviour. *Nature* 534:206–212. [CrossRef](#) [Medline](#)
- Trang T, Al-Hasani R, Salvemini D, Salter MW, Gutstein H, Cahill CM (2015) Pain and poppies: the good, the bad, and the ugly of opioid analgesics. *J Neurosci* 35:13879–13888. [CrossRef](#) [Medline](#)
- Tritsch NX, Ding JB, Sabatini BL (2012) Dopaminergic neurons inhibit striatal output through non-canonical release of GABA. *Nature* 490:262–266. [CrossRef](#) [Medline](#)
- Vaughan CW, Christie MJ (1997) Presynaptic inhibitory action of opioids on synaptic transmission in the rat periaqueductal grey in vitro. *J Physiol* 498:463–472. [CrossRef](#) [Medline](#)
- Vaughan CW, Ingram SL, Connor MA, Christie MJ (1997) How opioids inhibit GABA-mediated neurotransmission. *Nature* 390:611–614. [CrossRef](#) [Medline](#)
- Wang S, Tan Y, Zhang JE, Luo M (2013) Pharmacogenetic activation of midbrain dopaminergic neurons induces hyperactivity. *Neurosci Bull* 29:517–524. [CrossRef](#) [Medline](#)
- Watanabe M, Narita M, Hamada Y, Yamashita A, Tamura H, Ikegami D, Kondo T, Shinzato T, Shimizu T, Fukuchi Y, Muto A, Okano H, Yamanaka A, Tawfik VL, Kuzumaki N, Navratilova E, Porreca F, Narita M (2018) Activation of ventral tegmental area dopaminergic neurons reverses pathological allodynia resulting from nerve injury or bone cancer. *Mol Pain* 14:1744806918756406. [CrossRef](#) [Medline](#)
- Wiklund L, Behzadi G, Kalén P, Headley PM, Nicolopoulos LS, Parsons CG, West DC (1988) Autoradiographic and electrophysiological evidence for excitatory amino acid transmission in the periaqueductal gray projection to nucleus raphe magnus in the rat. *Neurosci Lett* 93:158–163. [CrossRef](#) [Medline](#)